Related Experiment Video

Updated: Dec 7, 2025

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
11:02

Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development

Published on: October 30, 2013

21.5K

New and Emerging Therapies in the Management of Bladder Cancer

Chelsea K Osterman1, Matthew I Milowsky1,2

  • 1Department of Medicine, Division of Oncology, University of North Carolina School of Medicine, Houpt Physician's Office Building, 170 Manning Drive, CB #7305, Chapel Hill, NC, 27599, USA.

F1000Research
|September 28, 2020
PubMed

Insights

Recent advancements in bladder cancer treatment include seven new agents. This review discusses these new therapies, including immune checkpoint inhibitors and targeted drugs, and explores future combination treatments.

Area of Science:

  • Oncology
  • Pharmacology

Background:

  • The bladder cancer treatment landscape has rapidly evolved recently.
  • Seven new therapeutic agents have been approved in the last five years.
  • Novel drug classes offer improved outcomes for patients with previously limited options.

Purpose of the Study:

  • To review newly approved agents for bladder cancer treatment.
  • To highlight promising drugs and combination therapies in development.
  • To discuss immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates.

Main Methods:

  • Literature review of recent clinical trials and approvals.
  • Analysis of emerging therapeutic strategies in bladder cancer.
  • Synthesis of data on novel drug classes and combinations.

Main Results:

  • Significant progress has been made with the introduction of seven new agents.
  • New treatment options have improved outcomes for many patients.
  • Further research is needed to optimize patient selection and combination therapies.

Conclusions:

  • The current bladder cancer treatment landscape is dynamic and expanding.
  • Immune checkpoint inhibitors, targeted therapies, and antibody-drug conjugates show promise.
  • Optimizing the use of these agents and their combinations is a key future direction.
Keywords:
antibody-drug conjugateimmunotherapymetastaticmuscle-invasive bladder cancertargeted therapyurothelial carcinoma

More Related Videos

An Orthotopic Bladder Cancer Model for Gene Delivery Studies07:48

An Orthotopic Bladder Cancer Model for Gene Delivery Studies

Published on: December 1, 2013

12.9K
An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment08:43

An Orthotopic Bladder Tumor Model and the Evaluation of Intravesical saRNA Treatment

Published on: July 28, 2012

15.1K

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.4K
Tumor Immunotherapy01:27

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
1.3K
Cancer Therapies02:49

Cancer Therapies

Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
9.6K
Urinary Tract Calculi III: Medical Management01:30

Urinary Tract Calculi III: Medical Management

The diagnosis of renal calculi involves several imaging techniques, including non-contrast CT scans and ultrasound. These methods help visualize kidney stones, assess their size and location, and detect possible obstructions. Additionally, Measuring urine pH is useful for diagnosing specific stone types, such as struvite (alkaline pH) and uric acid stones (acidic pH). Cystine stones are primarily linked to cystinuria, a genetic condition. A urinalysis helps detect blood in the urine (hematuria)...
123
Urinary Tract Calculi VI: Surgical Management01:25

Urinary Tract Calculi VI: Surgical Management

Procedures for Kidney StonesMedical intervention is necessary when kidney stones or renal calculi are too large to pass spontaneously (typically greater than 5 millimeters) when stones are accompanied by symptomatic infection (such as fever or pyelonephritis), when they impair kidney function, or when they cause persistent symptoms like severe pain, nausea, or urinary retention. Additionally, patients with only one kidney or those who cannot be treated with medical management also require...
197
Urinary Tract Infection IV: Nursing Management01:17

Urinary Tract Infection IV: Nursing Management

In managing urinary tract infections (UTIs) in nursing, a comprehensive assessment is essential. Begin by gathering subjective data, such as the patient’s complaints of dysuria (painful urination), urinary frequency, urgency, suprapubic pain, and any lower abdominal discomfort. This information can be complemented by questions regarding previous UTIs, sexual activity, and personal hygiene practices, which can provide insight into risk factors. Objective assessment should focus on signs...
270